Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 10/20 | 0.40 |
| ▸ | CNR2 | P34972 | 8/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3592525 | 0.87 | SMN1; SMN2 (0.42) | SMN1; SMN2KCNH2ALDH1A1MAPK1 | |
| SCHEMBL3591950 | 0.84 | CNR1 (0.45) | CNR1CNR2SMN1; SMN2 | |
| SCHEMBL3590472 | 0.83 | KDM4E (0.40) | KCNH2SCN5ASCN9A | |
| SCHEMBL3587027 | 0.79 | KCNH2 (0.38) | CNR1CNR2KCNH2 | |
| SCHEMBL3602199 | 0.78 | PTGDR2 (0.41) | ALDH1A1 | |
| SCHEMBL3593293 | 0.71 | CNR2 (0.48) | CNR1CNR2 | |
| SCHEMBL3603195 | 0.68 | CNR2 (0.42) | CNR1CNR2 | |
| SCHEMBL4357106 | 0.67 | CNR1 (0.47) | CNR1CNR2 | |
| SCHEMBL3591440 | 0.66 | CNR1 (0.46) | CNR1CNR2 | |
| SCHEMBL3591947 | 0.64 | CNR1 (0.39) | CNR1CNR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004240-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2010-01-07 | — | — | US | disclosed |
| US-20100004240-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2010-01-07 | — | — | US | disclosed |
| US-20100004240-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2010-01-07 | — | — | US | disclosed |
| WO-2008006795-A2 | INDOLE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004240-A1 | Indole Compounds | IDO1, TPH1, IDO2 | CNR1 43/4885CNR2 62/4885SMN1; SMN2 3448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.